Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 10/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | APEX1 | P27695 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1149307 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL3414993 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL15061117 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL3693152 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL3869911 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL14026071 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL8746667 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL407263 | 1.00 | SLC18A3 (0.59) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL15464620 | 0.98 | SLC18A3 (0.57) | SLC18A3MEN1KMT2ACYP2D6TSHR | |
| SCHEMBL15464618 | 0.98 | SLC18A3 (0.57) | SLC18A3MEN1KMT2ACYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11739047-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739047-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210179535-A1 | ALPHA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-06-17 | — | — | US | disclosed |
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2021-04-06 | — | — | US | disclosed |
| WO-2012113889-A1 | PROCESSES FOR THE STEREOSELECTIVE PREPARATION OF P-CHIRAL FOUR -COORDINATED PHOSPHORUS BORANE COMPOUNDS AND P-CHIRAL THREE-COORDINATED PHOSPHORUS COMPOUNDS | UNIVERSITY COLLEGE DUBLIN (IE) | 2012-08-30 | — | — | WO | disclosed |
| US-7507843-B2 | Stereoselective synthesis of certain trifluoromethyl-substituted alcohols | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1751170-A1 | CHIRAL PHOSPHORUS COMPOUNDS | UNIVERSITY COLLEGE DUBLIN (IE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005118603-A1 | CHIRAL PHOSPHORUS COMPOUNDS | UNIVERSITY COLLEGE DUBLIN (IE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179535-A1 | ALPHA-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | FABP1, FABP2, FABP4 | SLC18A3 1426/4885MEN1 4880/4885KMT2A 4609/4885 |
| US-10968163-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | FABP1, FABP2, FABP4 | SLC18A3 1357/4885MEN1 4877/4885KMT2A 4537/4885 |
| US-11739047-B2 | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof | FABP1, FABP2, FABP4 | SLC18A3 1426/4885MEN1 4880/4885KMT2A 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.